CPT code 87532 represents a molecular diagnostic assay for Herpesvirus 6 (HHV-6) that uses amplified nucleic acid probe techniques. This laboratory procedure identifies HHV-6 nucleic acid to support diagnosis of conditions ranging from childhood roseola to more severe HHV-6–associated disease in immunocompromised adults. As molecular diagnostics play a growing role in infectious disease management, accurate coding for these assays affects clinical workflows, coverage determinations, and claims processing nationwide.

Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context for HHV-6 testing, the typical laboratory service setting for the assay, and what to expect in payer coverage discussions. The publication also outlines common billing considerations, typical sites of service, and the broader relevance of amplified nucleic acid probe testing in diagnostic laboratories.

This summary serves a national audience and highlights where CPT code 87532 fits within molecular infectious disease testing, what clinicians and billers should know about the test's purpose, and the types of payer and policy conversations that commonly surround high-complexity molecular assays.